Turn Therapeutics, Inc. (NASDAQ: TTRX) said it has completed a comprehensive interim analysis of its adaptive Phase 2 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE